The evidence provided suggested that the use of these drugs results in not only a short-term

increase in sex hormone-binding globulin (SHBG), but also a long-term effect, even years after the drugs have been discontinued. The clinical import of this observation is that testosterone levels in women, which are related to sexual desire, remain suppressed for years because of the high affinity Inhibitors,research,lifescience,medical binding of the testosterone to the SHBG. The investigators suggested that the ideal contraceptive in young women may be the intrauterine device rather than OCPs, and treatment with testosterone supplementation in these women may improve their sexual desire. Peyronie’s Disease Many lectures and posters dealt with the topic of Peyronie’s Inhibitors,research,lifescience,medical disease (PD). According to several different

posters, it appears as if some investigators are considering the use of PDE inhibitors together with l-arginine in the treatment of patients with PD.8,9 The scientific rationale is that PDE inhibitors and l-arginine, when used on a daily basis, act as antifibrotic agents. Reports during the meeting suggest that the drugs are being used in 2 different settings: (1) when the patient is being observed early Inhibitors,research,lifescience,medical in the disease course and (2) when the patient is being treated with intralesional therapy or during the postoperative period. Most of the data presented consisted of small numbers of patient and nonrandomized trials, so it is still undecided whether Inhibitors,research,lifescience,medical the use of these agents will become more accepted in clinical practice over time.
Overactive bladder syndrome (OAB) as defined by the International Continence Society (ICS) consists of the presence of urinary urgency, with or without urge incontinence, usually with frequency and nocturia.1 The prevalence rates in both Inhibitors,research,lifescience,medical men and women in the United States is estimated at approximately 17%.1 The total cost of OAB for the year 2000 has been estimated at $12.6 billion.2 This cost is made up of diagnostic, treatment, routine care, consequence, and indirect costs from loss of productivity. Due to prevalence and cost of this condition, there

are significant resources being utilized to develop treatments that improve patient quality of life (QOL) and Small molecule library research buy reduce the financial burden to society. OAB is a medical problem largely due to its negative impact on daily QOL. The subjective impact of urinary frequency and urgency (with/without urge Urease incontinence) on psychosocial and physical well-being is an important aspect of caring for this group of patients. The severity and degree of bother associated with the symptoms of OAB can directly influence a person’s mobility, degree of social isolation, impairment in work-related activities, disruption of sleep, impairment of domestic and sexual life, and result in depression.3 Patients may also develop extreme coping strategies including self-imposed fluid restrictions, avoidance of social events and travel, and dependence on protective undergarments.